Upside:
-THRD +39% (announces Plan of Liquidation and Dissolution)
-VERV +24% (in 2H25, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for PCSK9 opt-in; Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9)
-VKTX +17% (PFE to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management)
-AREC +14% (unit ReElement Technologies Announces Progress on Private Patriotic Capital Financing, Commercial Equipment Expansion, and Strategic Outlook Amid China’s Critical Mineral Export Restrictions)
-IKT +12% (appoints David McIntyre CFO, effective immediately)
-BBY +10% (President Trump exempts multiple key electronic products from tariffs)
-CERT +10% (earnings, guidance)
-ELUT +8.8% (confirms no material impact from global tariffs)
-ANIX +6.6% (receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology)
-AAPL +6.4% (President Trump exempts multiple key electronic products from tariffs)
-PLTR +5.5% (reportedly NATO acquires Palantir’s Maven Smart System (MSS NATO) with the system is expected to be operational within the next 30 days)
-FATE +4.8% (receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE))
-INTC +4.0% (confirms it entered into a definitive agreement to sell 51% of its Altera business to Silver Lake based on ~$8.75B valuation)
-PTON +3.6% (Deutsche Bank Raised PTON to Buy from Hold, price target: $6.60 from $8.60)
-ESI +3.2% (Truist Raised ESI to Buy from Hold, price target: $24)
-NVDA +3.1% (President Trump exempts multiple key electronic products from tariffs; reportedly Nvidia and Alphabet invested into Safe Superintelligence (SSI), a startup co-founded by OpenAI's former chief scientist Ilya Sutskever)
-GS +2.5% (earnings, color)
-URGN +2.3% (announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers)
-LLY +2.2% (in 2H25, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for PCSK9 opt-in; PFE to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management)
-AVGO +2.0% (President Trump exempts multiple key electronic products from tariffs)
Downside:
-SGBX -34% (prices $8M private placement for 20.4M units at $0.392 each)
-ADTX -13% (subsidiary Adimune announces results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials)
-CRCT -3.5% (CitiGroup Cuts CRCT to Sell from Neutral, price target: $4)